Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Julphar
Medtronic
Johnson and Johnson
Cerilliant
Deloitte
Chubb
Baxter
Teva

Generated: May 21, 2018

DrugPatentWatch Database Preview

Skyepharma Ag Company Profile

« Back to Dashboard

What is the competitive landscape for SKYEPHARMA AG, and what generic alternatives to SKYEPHARMA AG drugs are available?

SKYEPHARMA AG has two approved drugs.

There is one US patent protecting SKYEPHARMA AG drugs.

There are forty patent family members on SKYEPHARMA AG drugs in thirteen countries.

Summary for Skyepharma Ag
International Patents:40
US Patents:1
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Skyepharma Ag

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Skyepharma Ag TRIGLIDE fenofibrate TABLET;ORAL 021350-002 May 7, 2005 BX RX Yes Yes 6,696,084 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Skyepharma Ag ISOSORBIDE MONONITRATE isosorbide mononitrate TABLET, EXTENDED RELEASE;ORAL 075166-001 Oct 7, 1999 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Skyepharma Ag TRIGLIDE fenofibrate TABLET;ORAL 021350-001 May 7, 2005 DISCN No No 6,696,084 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Skyepharma Ag

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,703,202 Coated tablets ➤ Try a Free Trial
6,534,088 Fibrate-statin combinations with reduced fed-fasted effects ➤ Try a Free Trial
8,586,094 Coated tablets ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Baxter
Daiichi Sankyo
Merck
Healthtrust
Queensland Health
Citi
Fuji
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.